Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutic Discovery

Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells

Bin-Xia Yang, Yong-Juan Duan, Cheng-Ya Dong, Fang Zhang, Wei-Feng Gao, Xue-Ying Cui, Yong-Min Lin and Xiao-Tong Ma
Bin-Xia Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong-Juan Duan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng-Ya Dong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fang Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei-Feng Gao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xue-Ying Cui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong-Min Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao-Tong Ma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-10-0863 Published April 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    TPA induces the expression of mda-7/IL-24 and IL-24 delE5 in U937 and HL60 cell lines. U937 and HL60 cells were treated with 20 nmol/L TPA for 0, 24, 48, or 72 hours. A, RT-PCR was done by using primers for mda-7/IL-24 and GAPDH. B, the relative expression levels of mda-7/IL-24 and IL-24 delE5 were analyzed by quantitative real-time RT-PCR in U937 and HL60 cells treated with TPA for 48 hours. Threshold cycle of amplified products, which were amplified by using primers specific to mda-7/IL-24 and IL-24 delE5, is shown. C, the expression of mda-7/IL-24 and IL-24 delE5 protein was assessed by Western blotting. Representative results from 3 independent experiments are shown.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    RNA interference of the mda-7/IL-24 and IL-24 delE5 genes block TPA-induced monocytic differentiation of U937 and HL60 cells. U937 and HL60 cells were transfected with 100 nmol/L siRNA corresponding to mda-7/IL-24, IL-24 delE5, or nontargeting siRNA (NT). After transfection, differentiation was induced by addition of TPA. A, after 48 hours, the expression of mda-7/IL-24 and IL-24 delE5 protein was assessed by Western blotting, Bands were quantified by scanning densitometry by an LKB Ultrascan XL Laser Densitometer (Kodak Ltd.). B, after 72 hours, monocytic surface markers CD11b, CD14, and CD115 were analyzed by FACS. Results are expressed as the mean ± SD of 3 independent experiments (P < 0.05).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Regulation of TPA-induced mda-7/IL-24 and IL-24 delE5 expression and differentiation through the MAPK/ERK pathway in U937 and HL60 cells. U937 and HL60 cells were pretreated with or without the MEK inhibitor U0126 or PD98059 for 30 minutes and subsequently exposed to TPA for 72 hours. A and B, the phosphorylated, total ERK1/2, and mda-7/IL-24 and IL-24 delE5 proteins were determined by Western blotting by using specific antibodies. C, the expression of CD11b, CD14, and CD115 was estimated by FACS analysis. Data are presented as mean ± SD of 3 independent experiments (P < 0.001). D, cellular morphologic changes associated with differentiation were detected with Wright–Giemsa staining. Representative micrographs from 3 independent experiments with similar results are shown. Leica DM4000B microscope, ×40/0.75 HCL PL objective lens, Leica DC500 digital camera. Original magnifications, ×200 (i, iii) and ×1,000 (ii, iv).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Ectopic overexpression of mda-7/IL-24 and IL-24 delE5 induces differentiation of leukemic cells. U937 and HL60 cells, and blasts from 3 patients with AML-M5 were transfected with mda-7/IL-24, IL-24 delE5, or the empty vector as a negative control. A, after 48 hours, the expression of mda-7/IL-24 and IL-24 delE5 protein was detected by Western blotting in U937 and HL60 cells. B, after 72 hours, the expression of CD11b, CD14, and CD115 in U937 and HL60 cells was assessed by FACS. Results are expressed as the mean ± SD of 3 independent experiments (P < 0.05). C, after 72 hours, the morphologic changes in blasts from AML patients were analyzed with Wright–Giemsa staining. Arrows indicate the differentiated cells with nuclear condensation and decreased nuclear to cytoplasmic ratio. Leica DM4000B microscope, ×40/0.75 HCL PL objective lens, Leica DC500 digital camera. Original magnifications, ×1,000. D, the expression of CD11b, CD14, and CD115 in blast cells was assessed by FACS.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    mda-7/IL-24 and IL-24 delE5 have no effect on normal hematopoietic progenitors. Purified CD34+ cells were transfected with mda-7/IL-24 or IL-24 delE5. A, the colonies of CFU-GM, BFU-E, and CFU-GEMM were scored. Results are expressed as the mean ± SE of 3 independent experiments (P > 0.05). B, the expression of CD11b, CD14, and CD115 on cells cultured in liquid medium was detected by FACS on the indicated days. Data are presented as mean ± SD of 3 independent experiments (P < 0.05).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    mda-7/IL-24 and IL-24 delE5 induce differentiation of leukemic cells by inducing ROS production. U937 and HL60 cells, and blasts from patients with AML-M5 were transfected with mda-7/IL-24 or IL-24 delE5. A, after transfection, cells were cultured for 48 hours, ROS was monitored by FACS. Data are presented as mean ± SD of 3 independent experiments (P < 0.05). B, after transfection, cells were cultured in medium with or without 25 μmol/L NAC for 72 hours. The expression of CD11b, CD14, and CD115 was assessed by FACS. Results are expressed as the mean ± SD of 3 independent experiments from each cell line (P < 0.05). C, after transfection, cells were cultured in medium with or without 10 μmol/L DPI for 48 hours; ROS was monitored by FACS. Data are presented as mean ± SD of 3 independent experiments (P < 0.05). D, NADPH oxidase activity was measured 48 hours after transfection. Data represent the mean ± SE; P < 0.05, compared with vector control. Data are representative of at least 3 different experiments.

Additional Files

  • Figures
  • Supplementary Data, Yang, et al.

    Files in this Data Supplement:

    • Supplementary Figure 1
    • Supplementary Figure 2
    • Supplementary Figure 3
    • Supplementary Figure 4
    • Supplementary Figure 5
    • Supplementary Materials and Methods, Figure Legends 1-5
PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (4)
April 2011
Volume 10, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Bin-Xia Yang, Yong-Juan Duan, Cheng-Ya Dong, Fang Zhang, Wei-Feng Gao, Xue-Ying Cui, Yong-Min Lin and Xiao-Tong Ma
Mol Cancer Ther April 1 2011 (10) (4) 615-625; DOI: 10.1158/1535-7163.MCT-10-0863

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Bin-Xia Yang, Yong-Juan Duan, Cheng-Ya Dong, Fang Zhang, Wei-Feng Gao, Xue-Ying Cui, Yong-Min Lin and Xiao-Tong Ma
Mol Cancer Ther April 1 2011 (10) (4) 615-625; DOI: 10.1158/1535-7163.MCT-10-0863
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sorafenib Targets VCP in Hepatocellular Cancer Cells
  • RSK2 as Therapeutic Target for Myeloma
  • Dll4-Fc Suppresses Liver Metastasis of SCLC Cells
Show more Therapeutic Discovery
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement